These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

691 related articles for article (PubMed ID: 11786661)

  • 1. Medical treatment of primary biliary cirrhosis and primary sclerosing cholangitis.
    Holtmeier J; Leuschner U
    Digestion; 2001; 64(3):137-50. PubMed ID: 11786661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medical treatment of primary biliary cirrhosis and primary sclerosing cholangitis.
    Rust C; Beuers U
    Clin Rev Allergy Immunol; 2005 Apr; 28(2):135-45. PubMed ID: 15879619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment of cholestatic liver diseases with ursodeoxycholic acid].
    Boberg KM; Schrumpf E
    Tidsskr Nor Laegeforen; 1997 Sep; 117(23):3370-3. PubMed ID: 9411890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment of cholestatic liver diseases].
    Gatzen M; Pausch J
    Med Klin (Munich); 2002 Mar; 97(3):152-9. PubMed ID: 11957790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of cholestatic disease in 2017.
    de Vries E; Beuers U
    Liver Int; 2017 Jan; 37 Suppl 1():123-129. PubMed ID: 28052628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Latest and emerging therapies for primary biliary cirrhosis and primary sclerosing cholangitis.
    Zein CO; Lindor KD
    Curr Gastroenterol Rep; 2010 Feb; 12(1):13-22. PubMed ID: 20425480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liver transplantation for primary biliary cirrhosis and primary sclerosing cholangitis: does medical treatment alter timing and selection?
    Hay JE
    Liver Transpl Surg; 1998 Sep; 4(5 Suppl 1):S9-17. PubMed ID: 9742489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis.
    Smith T; Befeler AS
    Curr Gastroenterol Rep; 2007 Mar; 9(1):54-9. PubMed ID: 17335678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Case-control study on prednisolone combined with ursodeoxycholic acid and azathioprine in pure primary biliary cirrhosis with high levels of immunoglobulin G and transaminases: efficacy and safety analysis.
    Fang YQ; Lv DX; Jia W; Li J; Deng YQ; Wang Y; Yu M; Wang GQ
    Medicine (Baltimore); 2014 Oct; 93(20):e104. PubMed ID: 25365404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined therapy with azathioprine, prednisolone, and ursodiol in patients with primary sclerosing cholangitis. A case series.
    Schramm C; Schirmacher P; Helmreich-Becker I; Gerken G; zum Büschenfelde KH; Lohse AW
    Ann Intern Med; 1999 Dec; 131(12):943-6. PubMed ID: 10610645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug Therapies for Chronic Cholestatic Liver Diseases.
    Wagner M; Fickert P
    Annu Rev Pharmacol Toxicol; 2020 Jan; 60():503-527. PubMed ID: 31506007
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel and emerging therapies for cholestatic liver diseases.
    Goldstein J; Levy C
    Liver Int; 2018 Sep; 38(9):1520-1535. PubMed ID: 29758112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary sclerosing cholangitis.
    Stiehl A; Benz C; Sauer P
    Can J Gastroenterol; 2000 Apr; 14(4):311-5. PubMed ID: 10799084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of autoimmune and cholestatic liver disorders.
    Krok KL; Munoz SJ
    Clin Liver Dis; 2009 May; 13(2):295-316. PubMed ID: 19442920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bile acid therapy and markers of immune-mediated damage in primary biliary cirrhosis.
    de Caestecker JS
    Eur J Gastroenterol Hepatol; 1997 Feb; 9(2):145-7. PubMed ID: 9058624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of primary biliary cholangitis with ursodeoxycholic acid, prednisolone and immunosuppressants in patients not responding to ursodeoxycholic acid alone and the prognostic indicators.
    Qian JD; Yao TT; Wang Y; Wang GQ
    Clin Res Hepatol Gastroenterol; 2020 Nov; 44(6):874-884. PubMed ID: 32305248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action.
    Poupon R
    Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S3-12. PubMed ID: 23141891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of primary biliary cirrhosis: therapy with choleretic and immunosuppressive agents.
    Silveira MG; Lindor KD
    Clin Liver Dis; 2008 May; 12(2):425-43; x-xi. PubMed ID: 18456189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current treatments of primary sclerosing cholangitis.
    Vacca M; Krawczyk M; Petruzzelli M; Sasso RC; van Erpecum KJ; Palasciano G; van Berge-Henegouwen GP; Moschetta A; Portincasa P
    Curr Med Chem; 2007; 14(19):2081-94. PubMed ID: 17691949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Obeticholic acid for the treatment of primary biliary cholangitis.
    Ali AH; Lindor KD
    Expert Opin Pharmacother; 2016 Sep; 17(13):1809-15. PubMed ID: 27468093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.